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SUMMARY
Purpose: To estimate the burden of lifetime epilepsy
(LTE) and active epilepsy (AE) and examine the influence
of study characteristics on prevalence estimates.
Methods: We searched online databases and identified
articles using prespecified criteria. Random-effects meta-
analyses were used to estimate the median prevalence in
developed countries and in urban and rural settings in
developing countries. The impact of study characteristics
on prevalence estimates was determined using meta-
regression models.
Results: The median LTE prevalence for developed coun-
tries was 5.8 per 1,000 (5th–95th percentile range 2.7–
12.4) compared to 15.4 per 1,000 (4.8–49.6) for rural and
10.3 (2.8–37.7) for urban studies in developing countries.
The median prevalence of AE was 4.9 per 1,000 (2.3–10.3)
for developed countries and 12.7 per 1,000 (3.5–45.5) and
5.9 (3.4–10.2) in rural and urban studies in developing
countries. The estimates of burden for LTE and AE in
developed countries were 6.8 million (5th–95th percentile
range 3.2–14.7) and 5.7 million (2.7–12.2), respectively. In
developing countries these were 45 (14–145) million LTE
and 17 (10–133) million AE in rural areas and 17 (5–61)
million LTE and 10 (5–17) million AE in urban areas. Stud-
ies involving all ages or only adults showed higher esti-
mates than pediatric studies. Higher prevalence
estimates were also associated with rural location and
small study size.
Conclusions: This study estimates the global burden of
epilepsy and the proportions with AE, which may benefit
from treatment. There are systematic differences in
reported prevalence estimates, which are only partially
explained by study characteristics.
KEY WORDS: Epilepsy, Prevalence, Burden, Meta-
analysis.
Epilepsy is one of the most common neurologic condi-
tions in the world, but the current estimates of 50 million
people worldwide (WHO, 2004) lack precision and do not
provide an estimate of the proportion with active epilepsy
(AE), that is, those who may benefit from treatment.
The epidemiologic studies describing the burden of epi-
lepsy in the last 40 years are problematic (Kotsopoulos
et al., 2002; Kotsopoulos et al., 2005). Data on epilepsy are
still scarce in many parts of the world, whereas the available
data are inconsistent because of differences in sampling
frames, case definitions, measurements (e.g., point vs. per-
iod or lifetime prevalence), screening tools, diagnostic
accuracy, and different methodologic approaches (Leonardi
& Ustan, 2002).
In the developed world where routine medical statistics
are available and easily accessible, investigators have used
research and hospital databases rather than population-based
studies to estimate the prevalence of epilepsy. This practice,
however, discriminates against those who underutilize med-
ical services (Wright et al., 2000; Morgan et al., 2000).
Community-based surveys are more commonly used in
developing countries, but often do not make use of validated
tools to screen the population. Even where validated tools
are used, these studies may have higher sensitivity for con-
vulsive epilepsies, and thus more subtle forms of epilepsy
are underestimated (Da Mota et al., 2002; Racoosin, 2003).
The prevalence of epilepsy is reported to vary substan-
tially between developed and developing countries: esti-
mated as 4–7 per 1,000 persons in the developed countries,
(Sander & Shorvon, 1996) and 5–74 per 1,000 persons in
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developing countries (Preux & Druet-Cabanc, 2005). The
wider variations in the estimates of prevalence from
resource-poor compared to developed countries complicate
the use of these data in estimating the number who may ben-
efit from treatment and in informing public health policy.
Heterogeneity in prevalence estimates, although anecdot-
ally referred to, has not been investigated systematically.
The heterogeneity could be due to differences in the preva-
lence of causes, case definitions, or case ascertainment.
Knowledge of these factors would be useful in the design
and implementation of multisite studies of epilepsy. Fur-
thermore, differences in causes could have implications in
resource allocation in public health interventions.
We conducted a systematic review of published literature
to determine heterogeneity in prevalence between studies
and to provide estimates of the global burden of epilepsy, in
particular to provide numbers of those with AE who may
benefit from treatment. Furthermore, we modeled the influ-
ence of study level covariates on the prevalence estimates.
Methods
Literature searches
Online databases; MEDLINE, EMBASE, PsycINFO,
African Index Medicus, Index Medicus for South East Asia,
Index Medicus for Eastern Mediterranean Region, BVS
Virtual Health Library (Lilacs, Adolec, Medcarib, PAHO,
and WHOLIS), SIGLE, Proquest, Wang Fang Database of
English and Chinese online journals published in mainland
China, SCIELO, CINAHL, and Global Health were system-
atically searched by the first author. Reference lists of iden-
tified articles were also searched for relevant titles and these
were in turn searched online.
Search strategies
Where applicable, combined text words and Medical
Subject Headings (MeSH) terminology were used in addi-
tion to the two main search terms [Epilepsy & Prevalence]
to identify relevant articles (Table S1). Boolean operators
were used to combine search terms as necessary, and the
MeSH subheadings tree was used to increase the specificity
of the search terms in MEDLINE and EMBASE databases.
The review question was broken down into search terms/
elemental facets to develop a search strategy (Table S1).
This involved the use of the recommendations of the
National Health Service Centre for Reviews and Dissemina-
tions (Khan et al., 2001).
Study selection
We included retrospective, cross-sectional, or prospec-
tive population-based studies measuring prevalence of epi-
lepsy from anywhere in the world. Hospital-based and
medical records/research database studies were also exam-
ined. The estimate of the prevalence was obtained from
papers that met the criteria outlined below, which included
the International League Against Epilepsy (ILAE) defini-
tion of LTE and AE (Commission on Epidemiology and
Prognosis: International League Against Epilepsy, 1993).
An additional definition of AE that encompasses seizures
within the previous 12 months was also examined, since
this is the criteria used for treatment in many developing
countries.
Inclusion and exclusion criteria
A study was included if it reported prevalence of LTE or
AE; collected data using standardized previously validated
questionnaires in door-to-door surveys, valid hospital and
research databases, and general practice records; provided
the denominator to allow recalculation of the presented or
required estimates; and, included a definition of epilepsy as
two or more unprovoked seizures occurring at least 24 h
apart.
A study was excluded if it examined only acute symptom-
atic seizures, specific seizure patterns, or epileptic syn-
dromes, for example, absence seizures; was published as a
review, an editorial, an abstract only, a letter, or a comment;
was a study on subpopulations, for example, prevalence of
epilepsy on patients with a history of head trauma; or, was a
part of duplicate populations, that is, those in which the
same population overlapped different reports.
Data extraction
We extracted data using a form designed form to capture
the information of interest from the articles for this review.
AKN extracted all the data, whereas CRJCN reextracted
data from a sample of 10% of the studies. From each
included study we obtained information on author, country,
study type, study population, data collection and ascertain-
ment method(s), age of study subjects, and whether the esti-
mate was point or period prevalence. We used only studies
that reported crude prevalence. We calculated the 95% con-
fidence interval (95% CI) around the estimates where these
were not provided. All meta-analyses were carried out in
STATA 10 (StataCorp, College Station, TX, U.S.A.).
Analysis
In the summary tables, crude prevalence estimates
expressed as the number of cases per 1,000 population were
presented with their 95% CIs. For all meta-analyses, models
were fitted to logit-transformed observed prevalences. Esti-
mates of the median and 5th and 95th percentiles of the dis-
tribution of true prevalences (i.e., the distribution of study
prevalences that excludes variation due to sampling error)
were obtained by back-transforming estimates on the logit
scale to the prevalence scale.
The data were stratified on the World Bank classification
of level of economic development of the study country (The
World Bank, 2006), but because there were few studies, the
countries were classified as developed or developing. Stud-
ies from developing countries were stratified further into
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urban and rural. Studies were also classified by age into
those on all age groups (both children and adults), those on
adults only (>15 years of age), and those on children only
(£15 years of age). Studies reporting crude LTE and AE
prevalences were analyzed separately.
Description of heterogeneity
We used forest plots (Lewis & Clarke, 2001) to visualize
the heterogeneity among the studies. The standard test for
heterogeneity, the Cochran chi-square (v2) test, was used to
examine the null hypothesis that the observed heterogeneity
was due sampling error (Higgins & Thompson, 2002).
Because heterogeneity was expected a priori due to clinical
and methodologic diversity in the studies, we also quantified
the degree of heterogeneity across studies using the statistic
I2 = ((Q)df)/Q) x 100%, whereQ is the Cochran chi-square
statistic and df is its degrees of freedom (Higgins & Thomp-
son, 2002; Higgins et al., 2003). I2 describes the percentage
of the variability in estimates that is due to true heterogeneity
(true differences in prevalence) rather than sampling error.
A value >50% is considered as substantial heterogeneity.
The median of the logit-transformed prevalences was
estimated from the random effects model using the com-
mand ‘‘meta’’ in STATA (StataCorp). In addition the 5th
and 95th percentiles were estimated as m € 1.96s, where s
is the standard deviation of the random effect, that is, the
standard deviation of the true study prevalences on the logit
scale. These quantities were then back-transformed to the
original prevalence scale. This approach uses information
on prevalence and study size (or equivalently, standard
errors/confidence intervals) and is applicable when there is
significant heterogeneity (Goodman, 1989). It involves an
assumption that the outcomes (such as logit prevalences)
being estimated in the different studies are not identical, but
follow a normal distribution, allowing for among-study
variation (Goodman, 1989).
Estimation of the number of epilepsy cases
Data on the mid-year population sizes of developed coun-
tries were obtained from the U.S. Census Bureau, Interna-
tional Data Base, (U.S. Census Bureau, 2007). Rural and
urban population sizes in developing countries were
obtained from the Columbia University’s Global Rural-
Urban Mapping Project (GRUMP) database (Center for
International Earth Science Information Network, 2009).
The numbers of cases of LTE and AE were estimated by
multiplying the estimated median prevalence obtained from
the meta-analysis by the average size of the population dur-
ing the period in which studies in this review were con-
ducted. A range was obtained using the 5th and 95th
percentiles.
Investigation of the sources of heterogeneity
The following five study level covariates were investi-
gated for their association with prevalence estimates: level
of economic development, age of study participants,
method of data collection, type of estimate (point or period
prevalence), and study size. The influence of these vari-
ables on study prevalence was investigated using random
effects meta-regression models. The models were fitted
using the ‘‘metareg’’ command in STATA (StataCorp).
This approach assumes two additive components of vari-
ance, one representing the variance within studies (i.e.,
error variance), and the other the variance between studies.
The regression coefficients represent log odds ratios
(ORs), since the models are fitted to logit-transformed
data. The proportion of heterogeneity explained by each of
the covariates was estimated by comparing the between-
studies component of variance in the null model (s0
2)
with the estimate of s2 for the model including covariates
((s0
2– s2)/ s0
2).
Both univariate and multivariable meta-regression were
performed. Variables that were significant in the univariate
analysis were included in the multivariable model using a
forward-selection strategy. The order in which variables
were introduced into the multivariate model was determined
by the size of the p-value in the univariate analysis (starting
with the smallest p-value). No further variables were intro-
duced when p > 0.05 for the introduced variable.
Results
Studies identified
Literature searches from all sources were as displayed
in Fig. 1. Reasons for exclusion of the 136 studies that
Figure 1.
Literature search and identification of studies for the meta-
analysis.
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underwent full text review are displayed in Table S2. Of
the 65 studies included (Tables S3a and b), 28 reported LTE
prevalence only, 18 reported both LTE and AE prevalence,
and 19 reported prevalence of AE only. Thirty-four were
from developing countries and 31 were from developed
countries. Among studies from developing countries, LTE
was reported in 16 studies from rural areas and 9 studies
from urban areas. AE was reported in nine studies from rural
areas and four from urban areas. Thirty-seven studies were
conducted in both adults and children, 17 were in children
only, and 11 were in adults only.
Period prevalence was estimated in 20 of the studies,
whereas point prevalence was estimated in the rest. The
studies did not all use the same methods for data collection:
20 studies used primarily medical records, 35 used question-
naires in cross-sectional field surveys, and 10 used medical
records to ascertain cases identified through questionnaires.
Sixty reports were written in English, four were Spanish,
and one was in French.
Three studies from developing countries defined AE as
epilepsy in which the last seizure occurred in the previous
12 months.
Description of heterogeneity for studies of LTE
Most of the variability in prevalence estimates was attrib-
utable to study heterogeneity (I2 = 98%, p < 0.001)
(Fig. 2), both from developed (I2 > 99%; p < 0.001) and
developing countries (I2 = 98%; p < 0.001) (Figs. S1 and
S2, respectively). The estimates also showed significant het-
erogeneity (I2 > 90%) after stratifying on age of study sub-
jects and rural/urban locations for developing countries.
The estimated median prevalence for developed countries
was 5.8 per 1,000 (5th–95th percentile range 2.7–12.4). In
developing countries, the median prevalence and range of
LTE was 15.4 per 1,000 (4.8–49.6) in rural areas and 10.3
per 1,000 (2.8–37.7) in urban areas (Table 1).On stratifica-
tion by the age of study subjects, the median prevalence and
5th–95th percentile range was: 9.7 per 1,000 (4.6–20.5) for
all age groups, 11.3 per 1,000 (4.2–30.5) for studies with
adults only, and 6.7 per 1,000 (1.6–27.2) for studies of
children only.
Description of heterogeneity for studies of AE
The estimated median prevalence of AE for developed
countries was 4.9 per 1,000 (5th–95th percentile range 2.3–
10.3). In the developing countries, the median prevalence
and range of AE was 12.7 per 1,000 (3.5–45.4) in rural areas
and 5.9 per 1,000 (3.4–10.2) in urban areas (Table 1).
When stratified on age of study participants, the median
prevalence and range was 7.0 per 1,000 (2.9–16.8) for all
ages, 7.0 per 1,000 (2.4–20.6) for adults, and 4.7 per 1,000
(3.3–6.9) for pediatric studies. There was substantial hetero-
geneity in the estimates, (I2 = 90%, p < 0.001).
Estimates of the number of epilepsy cases
The estimated median number of people with LTE in
developed countries was 6.8 million (5th–95th percentile
range 3.2–14.7 million) and for AE it was 5.7 million (2.7–
12.2 million). In the developing countries, the median and
range of LTE cases were 45 million (14–145 million) in
rural areas and 17 million (5–61 million) in urban areas. AE
constituted 38% of LTE cases in rural and 59% in urban
areas (Table 1).
Sources of heterogeneity in studies of LTE prevalence
In the univariate analysis, study size explained 45.3% of
the observed heterogeneity and studies with fewer than
1,000 subjects were more likely to have higher prevalence
estimates than were larger studies (p < 0.001). The develop-
ment level of the study country explained 26.4% of the
Figure 2.
Forest plot for life-time epilepsy
(LTE) prevalence per 1,000 persons
(all studies).
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between-study variance. In developing countries, studies
from both urban and rural areas had roughly 2 times or more
the prevalence of those from developed countries (Table 2).
Age of subjects, method of data collection, and type of
estimate were not associated with prevalence. In the
multivariable regression for all LTE studies, rural areas of
developing countries, studies in all age groups, and small
studies (n £ 20,000) were significantly associated with the
prevalence estimates (Table S4); together, these variables
accounted for 52.8% of the observed heterogeneity.
Sources of heterogeneity in studies of AE prevalence
In the univariate analysis of all AE studies, country devel-
opment level and study size were significantly associated
with prevalence estimates (p < 0.05), explaining 31.7% and
26.4% of the observed heterogeneity, respectively. In the
developing countries, studies from rural areas had signifi-
cantly higher prevalence estimates (OR 2.5, 95% CI
1.7–3.8) relative to studies from developed countries. Small
study size (n < 1,000) was also associated with higher prev-
alence estimates (OR 3.4, 95%CI 1.7–6.6). In the multivari-
able analysis, rural areas and small study size (n < 1,000)
were significantly associated with prevalence estimates and
together accounted for 42% of the observed heterogeneity
(Table S5).
Discussion
This study describes the distribution of prevalence in
studies of people with LTE and AE across the world. Num-
bers of cases of LTE are provided for developed countries
as well as for rural and urban locations of developing coun-
tries. Combined, these numbers provide a global estimate of
cases of LTE that could be much higher than the figure of 50
Table 1. Median prevalence and numbers of cases of LTE and AE
Epilepsy type Region
Median prevalence/1,000
(5th–95th percentile range) Mean populationa
No. of cases in
millions median
(5th–95th percentile range)
Percent LTE
with AE
LTE Developed 5.8 (2.7–12.4) 1,184,235,962 6.8 (3.2–14.7) 84
Developing Ruralb = 15.4 (4.8–49.6)
Urban = 10.3 (2.8–37.7)
2,929,891,835
1,619,261,754
45(14–145)
17(10–133)
38
59
AE Developed 4.9 (2.3–10.3) 1,184,235,962 5.7 (2.7–12.2)
Developing Ruralc = 12.7 (3.5–45.4)
Urban = 5.9 (3.4–10.2)
2,929,891,835
1,619,261,754
17 (5–61)
10 (5–17)
aAveraged over the period the selected studies were conducted.
bOne study mixed rural and urban populations (not included in these analyses).
cOne study mixed rural/urban populations and one unknown (both not included in the analysis).
AE, active epilepsy; LTE, life-time epilepsy.
Table 2. Random-effects meta-regression of prevalence of life-time epilepsy (LTE) from all studies, univariate
analyses (n = 46)
Covariate
Categories (1st listed is
reference)
No.
studies
Odds ratio
(95% CI) p-value
Heterogeneity
(s2)
Heterogeneity
(%)
Null model – 46 ) ) 0.53 )
Development Developed 20 1.0 )
Developing (Urban) 9 1.8 (1.1– 3.0) 0.03 0.39 (26.4)
Developing (Rural) 16 2.7 (1.8–4.0) <0.001
Age Adult 7 1.0 –
Children 11 1.2 (0.7–2.2) 0.6 0.52 (2.0)
All 28 0.7 (0.4–1.2) 0.2
Data collection Records 11 1.0 –
Questionnaires 29 1.6(0.8–3.0) 0.2 0.52 (1.7)
Records and questionnaires 6 1.2 (0.6– 2.4) 0.7
Study size >20,000 19 1.0 ) ) )
1,000–20,000 22 1.9 (1.4–2.7) <0.001 0.29 (45.3)
<1,000 5 5.2 (2.9–9.5) <0.001
Estimate type Period 15 1.0 ) 0.54 ()2.3)
Point 31 1.0 (0.6–1.5) 0.9
CI, confidence interval.
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million estimated by the World Health Organization
(WHO) (WHO, 2004). The number of people with AE who
should be considered for treatment in each region is also
estimated. The studies included in these analyses, however,
showed considerable heterogeneity, which we quantified
using robust meta-analysis (Egger et al., 1997a,b; Higgins
& Thompson, 2002; Higgins et al., 2003). There was sub-
stantial variation in the prevalence of both LTE and AE,
even within studies of similar age group or level of eco-
nomic development. Other estimates of the prevalence of
LTE from developed countries, (Sander & Shorvon, 1996)
and from developing countries, (Preux & Druet-Cabanc,
2005) are within the ranges reported in this study.
In this meta-analysis the prevalence of LTE is higher in
studies of adults than studies of all ages (both adults and
children), whereas it is lowest in children. The median prev-
alence of AE was similar for studies on all ages and adults
only, but lower in studies on children. These data also
showed that small studies (n < 1,000), and studies con-
ducted in less-developed regions were associated with a
higher prevalence of epilepsy. In developing countries,
these data show that the prevalence of LTE is highest in
rural areas, with the urban estimates being midway between
those of rural areas and developed countries. In addition, the
prevalence of AE in urban areas of developing countries is
closer to that of developed countries, with that of rural areas
being considerably higher.
To the best of our knowledge, this is the first study that
comprehensively reviews and analyzes available literature
to provide robust estimates of the global burden of epilepsy,
assesses and quantifies the variability of the estimates, and
investigates the influence of study-level covariates on the
observed heterogeneity. The few reviews conducted previ-
ously have been regional, for example, Latin America (Bur-
neo et al., 2005), exploring incidence and prevalence only
(Burneo et al., 2005), incidence only (Kotsopoulos et al.,
2002; Kotsopoulos et al., 2005), or mortality only (Diop
et al., 2005; Forsgen et al., 2005). Furthermore, this is the
first study that provides an estimate of the burden of AE that
could benefit from treatment.
The difference in heterogeneity of LTE prevalence esti-
mates between developed and resource-poor countries can
be explained in part by the fact that medical records, used
primarily to ascertain cases in developed countries, are to
some extent standardized, and provide consistent, detailed
information on patients leading to less variation in recorded
data. Where available, medical records are also used to
ascertain cases identified through questionnaires. Further-
more, the smaller amount of variation in studies from devel-
oped countries could be caused by the use of single district,
regional, and/or national databases that use similar diagnos-
tic codes such as the National General Practice Study of Epi-
lepsy database in the United Kingdom. Others include use
of the diagnostic record system in Rochester, an area of
New York, NY, U.S.A. (Hauser et al., 1993; Da Mota et al.,
2002; Racoosin, 2003; Tidman et al., 2003) or the use of the
Health Maintenance Organizations’ records (Annegers
et al., 1999; Holden et al., 2005).
Previously, data from developing countries were thought
to vary widely due to differences in methodology (such as
the use of nonstandard screening tools), and differences in
definitions, diagnosis, and classification (Leonardi & Ustan,
2002; Preux & Druet-Cabanc, 2005). The selection criteria
for our meta-analyses and the meta-regression models sug-
gest, however, that these factors account for an insignificant
amount of variation. Rather, age of study participants and
sample size are more important causes of the observed het-
erogeneity. These factors may be further compounded by
poor health care and lack of specialized medical personnel
and diagnostic equipment. This is particularly evident given
that the prevalence estimates for urban areas, with higher
concentration of health facilities and specialists, are midway
between those of rural areas and the developed countries.
The higher estimates of LTE prevalence in developing
countries are likely to be due to higher incidence of epilepsy
(Sander & Shorvon, 1996), which could in turn be attribut-
able to infectious etiology, particularly in rural areas
(Ogunniyi et al., 1987; Matuja et al., 2001; Preux &
Druet-Cabanc, 2005).
The trend toward a higher prevalence of AE is also appar-
ent in rural areas of developing countries. A much lower
prevalence of AE in urban areas that closely approximates
estimates from developed countries could be due to better
access to health services, diagnosis, and management. Rural
areas of developing countries have a large burden of
untreated epilepsy possibly due to stigma, beliefs and
attitudes about causes and consequences of epilepsy and
limited access to health services. Furthermore, recall of sei-
zure events over a 5-year period may be poorer in rural areas
due to low literacy levels and may lead to underestimation
of prevalence (Saha et al., 2008).
The proportions of people with AE are higher in devel-
oped countries and urban areas of developing countries
than in rural areas. This could be due to higher mortality
in the latter, though few data on epilepsy mortality in
developing countries are available and these are not segre-
gated for rural and urban areas (Carpio et al., 2005; Diop
et al., 2005). This could imply that people with better
controlled seizures live longer on average even though
they may continue to experience seizures. We have esti-
mated the prevalence of the treatment gap to be 56%
(95% CI 31–100%) in developing countries, with higher
estimates for rural areas (Mbuba et al., 2008). The better
access to healthcare in urban areas of developing coun-
tries and in developed countries suggests that not only
management of seizures but also the less severe life-
threatening etiologies improve life-expectancy.
The higher estimates of heterogeneity observed in rural
areas could be due to spatial clustering of risk factors, par-
ticularly parasites (Brooker et al., 2006), associated with
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development of epilepsy. This observation could be partly
due to clustering of genetic risk factors in rural areas, where
relatives tend to live in proximity.
Small study size (fewer than 20,000 subjects screened)
was associated with a higher prevalence of epilepsy, possi-
bly because some studies are conducted in communities
where the prevalence of epilepsy is suspected to be high.
For instance, one study was in a small isolated population
of Panamanian Indians where apparently a family history
of epilepsy was a significant risk factor (risk ratio = 14)
(Gracia et al., 1990).
The prevalence of epilepsy is determined by the rate at
which new cases arise and the rate at which existing cases
are lost due to death and recovery. The prevalence of LTE
increases with age because there is, by definition, no recov-
ery. Therefore, the older an individual is the more likely
they are to have had epilepsy at some point during their life-
time. An association is observed between AE and age
because of a low rate of loss of AE cases (due to recovery
and death) from the population.
The variables location, age of study participants, and
study size taken together account for 53% of the variance in
prevalence of LTE. Therefore, much of the variation in
study prevalence is attributable to factors not considered in
this meta-analysis. For example, variability in the preva-
lence of genetic or parasitologic risk factors or the extent of
the treatment gap may be responsible for some of this unex-
plained variation.
Limitations of the study
The main assumption of estimates of the number of epi-
lepsy cases is that the studies used in the analysis are repre-
sentative of the populations of both developed and
developing countries. However, this is hardly the case, par-
ticularly as there are no data from many parts of the world.
The estimates presented in this study, therefore, need to be
interpreted judiciously.
The estimates presented in these analyses are likely to
be influenced by different demographic structures, particu-
larly between developed and developing countries. How-
ever, it was not possible to derive age-adjusted estimates,
mainly because studies presented different age categories,
if at all.
Despite the fact that there was no time-limit criterion for
inclusion, almost all the selected studies were published
after 1990. This was because of the definition criteria of
epilepsy used, which was introduced by the ILAE at this
time (Commission on epidemiology and prognosis: Inter-
national League Against Epilepsy, 1993). The definition of
AE often used in less-developed regions is at least two
unprovoked seizures one of which should be in the previ-
ous 12 months, but this was used in only three studies. It
would have been interesting to compare the mean pre-
valence estimates based on this definition from a larger
number of studies.
In the meta-regression analysis, the choice of covariates
was influenced by the availability of information and, there-
fore, heterogeneity could be explained only by factors for
which information was available. Ideally future studies
should include more appropriate factors, for example, level
of treatment gap, which may influence prevalence.
Conclusions
This study uses a meta-analysis to provide estimates of
the burden of epilepsy. We demonstrate substantial hetero-
geneity in estimates of the prevalence of epilepsy and iden-
tify factors responsible for this heterogeneity. This study
provides estimates of the burden of AE, which can be used
as a guide to the number of people who could benefit from
treatment.
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